» Articles » PMID: 24054861

Increased Expression of Phosphorylated NBS1, a Key Molecule of the DNA Damage Response Machinery, is an Adverse Prognostic Factor in Patients with De Novo Myelodysplastic Syndromes

Overview
Journal Leuk Res
Date 2013 Sep 24
PMID 24054861
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The expression of activated forms of key proteins of the DNA damage response machinery (pNBS1, pATM and γH2AX) was assessed by means of immunohistochemistry in bone marrow biopsies of 74 patients with de novo myelodysplastic syndromes (MDS) and compared with 15 cases of de novo acute myeloid leukemia (AML) and 20 with reactive bone marrow histology. Expression levels were significantly increased in both MDS and AML, compared to controls, being higher in high-risk than in low-risk MDS. Increased pNBS1 and γH2AX expression possessed a significant negative prognostic impact for overall survival in MDS patients, whereas pNBS1 was an independent marker of poor prognosis.

Citing Articles

Alternative Splicing Detection Tool-a novel PERL algorithm for sensitive detection of splicing events, based on next-generation sequencing data analysis.

Adamopoulos P, Theodoropoulou M, Scorilas A Ann Transl Med. 2018; 6(12):244.

PMID: 30069446 PMC: 6046290. DOI: 10.21037/atm.2018.06.32.


Quantitative analysis and study of the mRNA expression levels of apoptotic genes , and in the articular cartilage of an animal model of osteoarthritis.

Kourtis A, Adamopoulos P, Papalois A, Iliopoulos D, Babis G, Scorilas A Ann Transl Med. 2018; 6(12):243.

PMID: 30069445 PMC: 6046300. DOI: 10.21037/atm.2018.05.47.


Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.

Diamantopoulos M, Tsiakanikas P, Scorilas A Ann Transl Med. 2018; 6(12):241.

PMID: 30069443 PMC: 6046292. DOI: 10.21037/atm.2018.06.10.


Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era.

Perry C, Agarwal D, Abdel-Fatah T, Lourdusamy A, Grundy R, Auer D Oncotarget. 2014; 5(14):5764-81.

PMID: 25026297 PMC: 4170616. DOI: 10.18632/oncotarget.2180.